Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice

S Vasu, RC Moffett, Janie McCluskey, MH Hamid, Nigel Irwin, Peter Flatt

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Parenteral delivery of long-acting glucagon-like peptide-1 (GLP-1) mimetics has received much attention as a therapeutic option for diabetes. However, cell therapy-based GLP-1 treatments may provide a more physiological regulation of blood glucose. The present study assessed the effects of chronic GLP-1 delivery by cell therapy, using the GLP-1-secreting GLUTag cell line, in normoglycemic and streptozotocin-induced diabetic mice. GLUTag cell aggregates were transplanted into the subscapular region of mice. Over 30 days, cellular transplantation gave rise to encapsulated and well-vascularized growths, which contained immunoreactive GLP-1. Cell implantation was well tolerated and had no appreciable metabolic effects in normal mice. However, transplantation significantly (P
LanguageEnglish
Pages1077-1084
JournalGene Therapy
Volume20
Issue number11
DOIs
Publication statusPublished - 1 Nov 2013

Fingerprint

Glucagon-Like Peptide 1
Streptozocin
Cell- and Tissue-Based Therapy
Insulin
Transplantation
Blood Glucose
Cell Line
Therapeutics
Growth

Cite this

@article{9ce37fc11a22419ab60baa5a112f09c5,
title = "Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice",
abstract = "Parenteral delivery of long-acting glucagon-like peptide-1 (GLP-1) mimetics has received much attention as a therapeutic option for diabetes. However, cell therapy-based GLP-1 treatments may provide a more physiological regulation of blood glucose. The present study assessed the effects of chronic GLP-1 delivery by cell therapy, using the GLP-1-secreting GLUTag cell line, in normoglycemic and streptozotocin-induced diabetic mice. GLUTag cell aggregates were transplanted into the subscapular region of mice. Over 30 days, cellular transplantation gave rise to encapsulated and well-vascularized growths, which contained immunoreactive GLP-1. Cell implantation was well tolerated and had no appreciable metabolic effects in normal mice. However, transplantation significantly (P",
author = "S Vasu and RC Moffett and Janie McCluskey and MH Hamid and Nigel Irwin and Peter Flatt",
year = "2013",
month = "11",
day = "1",
doi = "10.1038/gt.2013.33",
language = "English",
volume = "20",
pages = "1077--1084",
journal = "Gene Therapy",
issn = "0969-7128",
number = "11",

}

Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice. / Vasu, S; Moffett, RC; McCluskey, Janie; Hamid, MH; Irwin, Nigel; Flatt, Peter.

In: Gene Therapy, Vol. 20, No. 11, 01.11.2013, p. 1077-1084.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice

AU - Vasu, S

AU - Moffett, RC

AU - McCluskey, Janie

AU - Hamid, MH

AU - Irwin, Nigel

AU - Flatt, Peter

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Parenteral delivery of long-acting glucagon-like peptide-1 (GLP-1) mimetics has received much attention as a therapeutic option for diabetes. However, cell therapy-based GLP-1 treatments may provide a more physiological regulation of blood glucose. The present study assessed the effects of chronic GLP-1 delivery by cell therapy, using the GLP-1-secreting GLUTag cell line, in normoglycemic and streptozotocin-induced diabetic mice. GLUTag cell aggregates were transplanted into the subscapular region of mice. Over 30 days, cellular transplantation gave rise to encapsulated and well-vascularized growths, which contained immunoreactive GLP-1. Cell implantation was well tolerated and had no appreciable metabolic effects in normal mice. However, transplantation significantly (P

AB - Parenteral delivery of long-acting glucagon-like peptide-1 (GLP-1) mimetics has received much attention as a therapeutic option for diabetes. However, cell therapy-based GLP-1 treatments may provide a more physiological regulation of blood glucose. The present study assessed the effects of chronic GLP-1 delivery by cell therapy, using the GLP-1-secreting GLUTag cell line, in normoglycemic and streptozotocin-induced diabetic mice. GLUTag cell aggregates were transplanted into the subscapular region of mice. Over 30 days, cellular transplantation gave rise to encapsulated and well-vascularized growths, which contained immunoreactive GLP-1. Cell implantation was well tolerated and had no appreciable metabolic effects in normal mice. However, transplantation significantly (P

U2 - 10.1038/gt.2013.33

DO - 10.1038/gt.2013.33

M3 - Article

VL - 20

SP - 1077

EP - 1084

JO - Gene Therapy

T2 - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 11

ER -